Page last updated: 2024-12-06
rpr 103611
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
RPR 103611: a statine derivative; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 72411 |
| CHEMBL ID | 7447 |
| MeSH ID | M0259102 |
Synonyms (16)
| Synonym |
|---|
| rpr 103611 |
| (3s,4s)-4-[8-[[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methyl-heptanoic acid |
| rpr103611 |
| 150840-75-8 |
| heptanoic acid, 3-hydroxy-4-[[8-[[(3.beta.)-3-hydroxy-28-oxolup-20(29)-en-28-yl]amino]-1-oxooctyl]amino]-6-methyl-, (3s,4s)- |
| CHEMBL7447 |
| (3s,4s)-4-[8-[[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carbonyl]amino]octanoylamino]-3-hydroxy-6-methylheptanoic acid |
| heptanoic acid, 3-hydroxy-4-((8-(((3-beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl)amino)-1-oxooctyl)amino)-6-methyl-, (s-(r*,r*))- |
| (s-(r*,r*))-3-hydroxy-4-((8-(((3-beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl)amino)-1-oxooctyl)amino)-6-methylheptanoic acid |
| n'-(n-(3-hydroxylup-20(29)-en-28-oyl)-8-aminooctanoyl)-4-amino-3-hydroxy-6-methylheptanoic acid |
| heptanoic acid, 3-hydroxy-4-((8-(((3beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl)amino)-1-oxooctyl)amino)-6-methyl-, (s-(r*,r*))- |
| (s-(r*,r*))-3-hydroxy-4-((8-(((3beta)-3-hydroxy-28-oxolup-20(29)-en-28-yl)amino)-1-oxooctyl)amino)-6-methylheptanoic acid |
| rpr-103611 |
| 4-[(8-{[3,28-dihydroxylup-20(29)-en-28-ylidene]amino}-1-hydroxyoctylidene)amino]-3-hydroxy-6-methylheptanoic acid |
| DTXSID10934100 |
| HY-146338 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (10)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1873270 | Antiviral activity against HIV-1 YU2 (R4) infected in human TZM-bl cells assessed as reduction in viral replication | 2022 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 69 | Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds. |
| AID78783 | Toxic concentration on HIV-1 mock infected H9 lymphocyte cells | 1996 | Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5 | Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. |
| AID1873273 | Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability by CellTitre-Glo assay | 2022 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 69 | Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds. |
| AID81588 | full Inhibitory activity against HIV-1-induced syncytia | 1996 | Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5 | Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. |
| AID1873272 | Antiviral activity against HIV-1 89.6 infected in human TZM-bl cells assessed as reduction in viral replication | 2022 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 69 | Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds. |
| AID78942 | Inhibitory activity against HIV-1 replication in mock infected H9 cells | 1996 | Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5 | Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. |
| AID1873274 | Selectivity index, ratio of CC50 for human TZM-bl cells to IC50 for IC50 for antiviral activity against HIV-1 89.6 infected in human TZM-bl cells | 2022 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 69 | Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds. |
| AID1873271 | Antiviral activity against HIV-1 NL4-3(X4) infected in human TZM-bl cells assessed as reduction in viral replication | 2022 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 69 | Design, synthesis, and bio-evaluation of novel triterpenoid derivatives as anti-HIV-1 compounds. |
| AID1706898 | Anti-HIV-1 activity against HIV1 IIIB infected in human H9 cells assessed as in p24 antigen production by sandwich ELISA | 2020 | Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24 | Triterpenoid-Mediated Inhibition of Virus-Host Interaction: Is Now the Time for Discovering Viral Entry/Release Inhibitors from Nature? |
| AID198243 | Inhibitory activity against HIV-RT; no inhibition | 1996 | Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5 | Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.62
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.62) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||